Hos patienter med kronisk nyreinsufficiens øgedes både AUC og den maksimale plasmakoncentration (Cmax) for loratadin og dets aktive metabolit sammenlignet med AUC og den maksimale plasmakoncentration (Cmax) hos patienter med normal nyrefunktion.
In patients with chronic renal impairment, both the AUC and peak plasma levels (Cmax) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (Cmax) of patients with normal renal function.